Hemorheological and Glycemic Parameters and HDL Cholesterol for the Prediction of Cardiovascular Events by 沅뚰쁺臾� & �씠蹂묎텒
Original Article
Hemorheological and Glycemic Parameters and HDL Cholesterol for 
the Prediction of Cardiovascular Events
Sung Woo Cho1,2, Byung Gyu Kim1, Byung Ok Kim1, Young Sup Byun1, Choong Won Goh1, Kun Joo Rhee1, Hyuck 
Moon Kwon3, Byoung Kwon Lee3
Division of Cardiology – Department of Internal Medicine – Sanggye Paik Hospital, Inje University College of Medicine1, Seoul; Division 
of Cardiology – Department of Medicine – Samsung Medical Center2, Seoul; Division of Cardiology – Department of Internal Medicine – 
Gangnam Severance Hospital – Yonsei University College of Medicine3, Seoul – Korea
Mailing Address: Byoung Kwon Lee  •
Division of Cardiology, Department of Internal Medicine, Gangnam 
Severance Hospital, Yonsei University College of Medicine. 
Postal Code 135‑720, 211 Eonju‑ro, Gangnam‑gu – Seoul
E‑mail: cardiobk@yuhs.ac
Manuscript received June 09, 2015; manuscript revised October 07, 2015; 
accepted October 14, 2015.
DOI: 10.5935/abc.20150146
Abstract
Background: Hemorheological and glycemic parameters and high density lipoprotein (HDL) cholesterol are used as 
biomarkers of atherosclerosis and thrombosis.
Objective: To investigate the association and clinical relevance of erythrocyte sedimentation rate (ESR), fibrinogen, 
fasting glucose, glycated hemoglobin (HbA1c), and HDL cholesterol in the prediction of major adverse cardiovascular 
events (MACE) and coronary heart disease (CHD) in an outpatient population.
Methods: 708 stable patients who visited the outpatient department were enrolled and followed for a mean period of 
28.5 months. Patients were divided into two groups, patients without MACE and patients with MACE, which included 
cardiac death, acute myocardial infarction, newly diagnosed CHD, and cerebral vascular accident. We compared 
hemorheological and glycemic parameters and lipid profiles between the groups.
Results: Patients with MACE had significantly higher ESR, fibrinogen, fasting glucose, and HbA1c, while lower HDL 
cholesterol compared with patients without MACE. High ESR and fibrinogen and low HDL cholesterol significantly 
increased the risk of MACE in multivariate regression analysis. In patients with MACE, high fibrinogen and HbA1c levels 
increased the risk of multivessel CHD. Furthermore, ESR and fibrinogen were significantly positively correlated with 
HbA1c and negatively correlated with HDL cholesterol, however not correlated with fasting glucose.
Conclusion: Hemorheological abnormalities, poor glycemic control, and low HDL cholesterol are correlated with each other 
and could serve as simple and useful surrogate markers and predictors for MACE and CHD in outpatients. (Arq Bras Cardiol. 
2016; 106(1):56-61)
Keywords: Atherosclerosis; Coronary Artery Disease; Blood Sedimentation; Fibrinogen; Cardiovascular Diseases / 
adverse events.
Introduction
Atherosclerosis, thrombosis, and plaque formation are 
progressive and dynamic consequences of the complex 
interactions between endothelial dysfunction, inflammation, 
and hemorheological factors. Hemorheological abnormalities 
may lead to elevated shear forces at the vascular endothelium 
by increasing red blood cell (RBC) aggregation and local blood 
viscosity, promoting endothelial injury.1 They may also trigger 
the rupture of lipid‑rich, unstable atherosclerotic lesion, thus 
leading to thrombus formation and clinical symptoms of acute 
coronary syndrome.2,3 These phenomena are indicated by 
several hemorheological parameters, including the acute phase 
reactants erythrocyte sedimentation rate (ESR) and fibrinogen,1,4 
which are therefore predictors and biomarkers of major adverse 
cardiovascular events (MACE), acute coronary syndrome, 
coronary heart disease (CHD), and ischemic stroke.5‑14
Hemorheological abnormalities such as increased blood and 
plasma viscosity, enhanced RBC aggregation, and decreased 
RBC deformability have been described in patients with 
diabetes mellitus (DM).15,16 Chronic complications of diabetes 
are macro‑ and micro‑vascular dysfunction, which may increase 
the potential for thrombosis and plaque formation and finally 
increase cardiovascular mortality. Furthermore, abnormalities 
in blood rheology are prominent in patients with poor glycemic 
control.15 Indeed, glycated hemoglobin (HbA1c), which is the 
parameter of glycemic control, has been reported as a predictor 
and risk factor of MACE, acute coronary syndrome, and CHD 
in both diabetic and non‑diabetic patients.17‑22 Also, it is well 
established that low high density lipoprotein (HDL) cholesterol 
level is a cardiovascular risk factor, negatively correlated with 
blood viscosity.23
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Previous studies have reported correlations between 
hemorheological abnormalities, poor glycemic control, 
and low HDL cholesterol.17,24,25 However, few reports 
have addressed such relationship by taking into account 
simultaneously these three risk factors.25 In the present study, 
we investigated the association of hemorheological and 
glycemic parameters with HDL cholesterol, and the clinical 
relevance of these factors in the prediction of MACE and CHD 
in an outpatient population.
Methods
Study population and design
From February 2007 to January 2009, 708 stable patients 
who visited the outpatient department were enrolled in the study 
and followed until June 2010. Patients with acute or chronic 
infection, inflammatory disease, liver failure, renal insufficiency, 
or cancer were excluded from the analysis. Hypertension was 
considered as the presence of repeated measurements of systolic 
blood pressure ≥ 140 mmHg and/or diastolic blood pressure 
≥ 90 mmHg, or antihypertensive drug treatment. DM was 
defined as a fasting blood glucose concentration ≥ 126 mg/dL 
or use of antihyperglycemic drugs. Smoking was assessed by a 
self‑administered questionnaire, with current smoking defined 
as any smoking within the past year. 
Patients were divided into two groups, patients with 
MACE and patients without MACE. MACE included 
cardiac death, acute myocardial infarction (AMI), newly 
diagnosed CHD, and cerebral vascular accident (CVA). 
Patients with AMI were diagnosed on the basis of clinical 
presentations, specific electrocardiographic alterations, 
and serum cardiac enzyme levels. CHD was diagnosed by 
coronary angiography or coronary computed tomography 
(CT) angiography. A significantly diseased artery was defined 
as having ≥ 50% stenosis in at least one of its segments. 
Patients with CVA were diagnosed on the basis of clinical 
presentations and cerebral imaging modality such as CT or 
magnetic resonance imaging.
We received approval from the institutional review board of 
Inje University Sanggye Paik Hospital, Seoul, Korea to conduct 
all these analyses. All subjects included gave their informed 
consent at the time of the examination.
Blood sampling and preparation
Blood samples were taken by venipuncture after an overnight 
fast from patients. Serum fasting glucose, total cholesterol, 
triglyceride, HDL cholesterol, low‑density lipoprotein (LDL) 
cholesterol, blood urea nitrogen (BUN), and creatinine 
levels were measured using dedicated reagents by automatic 
chemistry analyzer (AU 5400, Beckman‑Coulter, Fullerton, 
CA, USA). Complete blood count (CBC) was measured using 
XE‑2100 (Sysmex cooperation, Kobe, Japan). ESR was measured 
by Test‑1 analyzer (Alifax, Padova, Italy) and fibrinogen was 
determined using coagulometric techniques in a CA‑1500 
autoanalyzer (Sysmex). HbA1c was measured by a high‑pressure 
liquid chromatographic assay (G8 system, Tosoh, Japan). 
All of the laboratory parameters were determined in the central 
laboratory of the Inje University Sanggye Paik Hospital.
Statistical analysis
All data were analyzed using the PASW 18.0 software. 
Categorical variables were expressed as percentages and 
continuous variables as means ± standard deviation. 
Normally distributed continuous variables were compared using 
unpaired student t‑test, and categorical variables were compared 
using the chi‑squared test. Binary multivariate logistic regression 
analysis was performed, starting with a model including a number 
of potential confounders (age, gender, hypertension, diabetes, 
and total cholesterol levels). Spearman rank correlation test was 
used for correlation analyses of continuous parameters. p value 
of < 0.05 was considered statistically significant.
Results
MACE and baseline clinical characteristics in study 
population
The mean follow‑up period of the study population was 
28.5 months, and MACE occurred in 60 patients during this 
period. Three patients died (one because of sudden cardiac 
death and two because of heart failure), one patient was 
admitted due to AMI, 53 patients were newly diagnosed 
CHD, and 3 patients were admitted due to CVA (Table 1).
The patients with MACE were significantly older and 
had significantly higher incidence of hypertension and DM 
compared to patients without MACE. In addition, the patients 
with MACE had significantly lower levels of hemoglobin, 
hematocrit, platelet, and HDL cholesterol, while higher levels 
of ESR, fibrinogen, fasting glucose, and HbA1c compared to 
patients without MACE. The baseline clinical characteristics 
of the study population are summarized in Table 2.
Prediction of MACE, hemorheological parameters and HDL 
cholesterol
Logistic regression analysis was performed to identify 
the association between hemorheological and glycemic 
parameters and the risk of MACE (Table 3). In univariate 
analysis, higher level of ESR (OR 1.026, p = 0.001), 
fibrinogen (OR 1.005, p = 0.006), fasting glucose (OR 1.008, 
p = 0.016), and HbA1c (OR 1.358, p = 0.007) increased 
the risk of MACE. However, in multivariate analysis, only ESR 
(OR 1.021, p = 0.013) and fibrinogen (OR 1.004, p = 0.04) 
were significantly associated with the risk of MACE. 
Also, lower level of HDL cholesterol increased the risk 
of MACE in both univariate (OR 0.945, p < 0.001) and 
multivariate analysis (OR 0.948, p = 0.001).
Table 1 – Frequency (%) of events in 60 patients with adverse 
cardiac events
Events N (%)
Death 3 (5%)
Myocardial infarction 1 (1.7%)
Coronary heart disease 53 (88.3%)
Cerebrovascular accident 3 (5%)
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Table 2 – Baseline clinical characteristics of the study population
Variable MACE (-) (n = 648) MACE (+) (n = 60) p value
Age (years) 60.2 ± 13.5 66.1 ± 9.7 0.001
Gender (male), n (%) 336 (51.9%) 31 (51.7%) 1.00
Hypertension, n (%) 452 (69.8%) 50 (83.3%) 0.026
Diabetes mellitus, n (%) 125 (19.3%) 21 (35.0%) 0.007
Previous MI, n (%) 76 (11.7%) 8 (13.3%) 0.68
Previous CHD, n (%) 147 (22.7%) 20 (33.3%) 0.08
Smoking, n (%) 242 (37.3%) 26 (43.3%) 0.40
Hemoglobin (g/dL) 13.9 ± 1.7 13.4 ± 1.7 0.027
Hematocrit (%) 41.7 ± 4.4 40.2 ± 4.7 0.03
WBC (mm3) 6596 ± 1732 7096 ± 2041 0.07
Platelet (×103/mm3) 239.8 ± 60.0 219.3 ± 46.7 0.002
ESR (mm/h) 14.6 ± 13.3 21.3 ± 17.3 0.005
Fibrinogen (mg/dL) 292.4 ± 69.6 318.6 ± 58.2 0.002
Fasting glucose (mg/dL) 106.4 ± 28.6 117.0 ± 47.5 0.011
HbA1c (%) 5.9 ± 0.9 6.2 ± 1.0 0.014
Cholesterol (mg/dL) 191.4 ± 39.0 186.3 ± 52.9 0.35
LDL cholesterol (mg/dL) 121.1 ± 31.2 121.3 ± 42.5 0.95
HDL cholesterol (mg/dL) 48.8 ± 11.2 43.2 ± 9.2 < 0.001
Triglyceride (mg/dL) 156.5 ± 88.7 171.1 ± 115.2 0.24
BUN (mg/dL) 16.6 ± 5.8 16.8 ± 5.4 0.76
Creatinine (mg/dL) 1.07 ± 0.3 1.12 ± 0.3 0.28
MACE: major adverse cardiovascular events; MI: myocardial infarction; CHD: coronary heart disease; WBC: white blood cell count; ESR: erythrocyte sedimentation 
rate; HbA1c: glycated hemoglobin; LDL: low-density lipoprotein; HDL: high-density lipoprotein; BUN: blood nitrogen urea. Data in mean ± standard deviation.
Table 3 – Odds ratios for the association between hemorheological parameters, glycemic parameters and the risk of major adverse 
cardiovascular events
Univariate analysis Multivariate analysis*
Variable Odds ratio (95% CI) p value Odds ratio (95% CI) p value
ESR 1.026 (1.011-1.042) 0.001 1.021 (1.004-1.038) 0.013
Fibrinogen 1.005 (1.001-1.008) 0.006 1.004 (1.000-1.008) 0.04
Fasting glucose 1.008 (1.001-1.014) 0.016 1.004 (0.997-1.012) 0.26
HbA1c 1.358 (1.087-1.697) 0.007 1.225 (0.890-1.684) 0.21
HDL cholesterol 0.945 (0.917-0.974) < 0.001 0.948 (0.918-0.979) 0.001
*Age, gender, hypertension, diabetes, and cholesterol were included into the initial model. CI: confidence interval; ESR: erythrocyte sedimentation rate; HbA1c: glycated 
hemoglobin; HDL: high-density lipoprotein.
Prediction of CHD severity and hemorheological and 
glycemic parameters
Among the 53 patients of newly diagnosed CHD, 25 patients 
had one‑vessel disease and 28 patients had multivessel disease. 
The patients with multivessel disease had significantly higher 
levels of fibrinogen, fasting glucose, and HbA1c compared 
to patients with one‑vessel disease (Table 4). Among the 
hemorheological and glycemic parameters, higher level of 
fibrinogen (OR 1.013, p = 0.031 and OR 1.017, p = 0.032) 
and HbA1c (OR 2.519, p = 0.027 and OR 16.45, p = 0.015) 
increased the risk of multivessel CHD in both univariate and 
multivariate analysis, respectively (Table 5).
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Table 4 – Mean values of hemorheological and glycemic parameters according to the number of diseased coronary vessels in patients with 
coronary heart disease
Variable One-vessel disease (n = 25) Multivessel disease (n = 28) p value
ESR (mm/h) 19.4 ± 11.6 22.8 ± 20.3 0.46
Fibrinogen (mg/dL) 300.9 ± 46.7 336.1 ± 60.3 0.021
Fasting glucose (mg/dL) 104.2 ± 23.7 133.3 ± 63.1 0.035
HbA1c (%) 5.9 ± 0.6 6.7 ± 1.3 0.014
HDL cholesterol (mg/dL) 44.0 ± 9.6 41.7 ± 8.9 0.37
ESR: erythrocyte sedimentation rate; HbA1c: glycated hemoglobin; HDL: high-density lipoprotein. Data in mean ± standard deviation.
Table 5 – Odds ratios for the association between hemorheological and glycemic parameters and the risk of multivessel coronary artery disease
Univariate analysis Multivariate analysis*
Variable Odds ratio (95% CI) p value Odds ratio (95% CI) p value
ESR 1.014 (0.978-1.051) 0.47 1.022 (0.975-1.071) 0.36
Fibrinogen 1.013 (1.001-1.024) 0.031 1.017 (1.001-1.033) 0.032
Fasting glucose 1.017 (0.999-1.036) 0.07 1.017 (0.997-1.038) 0.10
HbA1c 2.519 (1.111-5.712) 0.027 16.45 (1.704-158.75) 0.015
HDL cholesterol 0.972 (0.915-1.033) 0.36 0.940 (0.872-1.012) 0.10
*Age, gender, hypertension, diabetes, and cholesterol were included into the initial model. CI: confidence interval; ESR: erythrocyte sedimentation rate; HbA1c: glycated 
hemoglobin; HDL: high-density lipoprotein.
Correlation of hemorheological and glycemic parameters 
with HDL cholesterol
Spearman univariate correlation analysis of hemorheological 
and glycemic parameters is shown in Table 6. ESR was 
significantly positively correlated with fibrinogen (r = 0.67, 
p < 0.001). Interestingly, ESR (r = 0.247, p < 0.001) 
and fibrinogen (r = 0.254, p < 0.001) were significantly 
positively correlated with HbA1c, but not with fasting glucose. 
In addition, HDL cholesterol was significantly negatively 
correlated with ESR (r = ‑0.079, p = 0.038), fibrinogen 
(r = ‑0.18, p < 0.001), fasting glucose (r = ‑0.158, p < 0.001), 
and HbA1c (r = ‑0.194, p < 0.001).
Discussion
In the present study, we investigated the association 
between hemorheological, glycemic parameters and HDL 
cholesterol, and the clinical relevance of these factors for 
the prediction of MACE and CHD in outpatient population.
ESR, fibrinogen, and C‑reactive protein are acute phase 
proteins whose concentrations increase in response to 
inflammation. Because chronic inflammation is involved 
in the progression of atherosclerosis and thrombosis, ESR 
and fibrinogen are elevated in cardiovascular disease and 
DM patients.6, 12 Our data also showed that higher ESR and 
fibrinogen are independent risk factor of MACE. The ESR 
is controlled by the balance between pro‑sedimentation 
factors, mainly fibrinogen, and those factors resisting 
sedimentation, especially the negative charge of the 
erythrocytes.2 When an inflammatory process is present, the 
increased concentration of fibrinogen in the blood causes 
RBC to stick to each other. Therefore, ESR and fibrinogen 
are hemorheological parameters which are represented as 
RBC aggregation and whole blood and plasma viscosity. 
In addition, our result showed that ESR was significantly 
positively correlated with fibrinogen.
DM is the most critical risk factor associated with 
cardiovascular disease and its chronic complications affect 
many organ systems. The precise mechanisms of diverse 
cellular and vascular dysfunction in DM are still being 
investigated. Among many mechanisms, hemorheological 
abnormalities are suggested to contribute to vascular 
dysfunction.15 However, there are few reports on the 
relationship between hemorheological factors and the status 
of glycemic control.26 Notably, our data showed that ESR and 
fibrinogen were significantly positively correlated with HbA1c, 
however not with fasting glucose. In addition, higher fibrinogen 
and HbA1c are independent risk factors of multivessel CHD 
in patients with MACE. Therefore, these data clearly indicated 
that poor glycemic control may cause hemorheological 
abnormalities and hence increase the risk of CHD.
Furthermore, our study showed that low HDL cholesterol 
significantly increased the risk of MACE, and HDL cholesterol 
was significantly negatively correlated with ESR, fibrinogen, 
fasting glucose and HbA1c. This result suggests an interaction 
between hemorheological parameters, glycemic parameters, 
and HDL cholesterol, which would contribute to the 
progression of atherosclerosis and thrombosis.
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